IMPROVING LIGAND PHARMACOKINETICS VIA BIOISOSTERIC SUBSTITUTION OF AMIDES WITH 1, 2, 3-TRIAZOLES WHILE MAINTAINING DOPAMINE D4 RECEPTOR SELECTIVITY AND POTENCY